<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005800</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-11971</org_study_id>
    <secondary_id>CA 82533</secondary_id>
    <nct_id>NCT00005800</nct_id>
  </id_info>
  <brief_title>Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer</brief_title>
  <official_title>A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel in treating&#xD;
      women who have stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the clinical and pathological response rate of sequential doxorubicin and&#xD;
           docetaxel chemotherapy in the neoadjuvant treatment of women with stage III breast&#xD;
           cancer.&#xD;
&#xD;
        -  Measure signal transducer and activator of transcription (STAT) activation before and&#xD;
           after this neoadjuvant chemotherapy regimen in this patient population.&#xD;
&#xD;
        -  Correlate response to chemotherapy with STAT activation before and after this&#xD;
           neoadjuvant chemotherapy regimen in these patients.&#xD;
&#xD;
        -  Determine how other potential predictors of response correlate with STAT activation by&#xD;
           measuring Bcl-2, Bcl-xL, Bax protein levels, tyrosine kinase levels, growth rate of the&#xD;
           tumor, and apoptotic index before and after this neoadjuvant chemotherapy regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Correlate response to chemotherapy with levels of STAT activation in association with&#xD;
           the presence of Bcl-2 proteins and tyrosine kinases, growth rate of the tumor, and&#xD;
           apoptotic index in these patients.&#xD;
&#xD;
        -  Evaluate the toxicity of this neoadjuvant chemotherapy regimen given in a dose-dense&#xD;
           fashion in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks&#xD;
      of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses.&#xD;
      Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and&#xD;
      docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo&#xD;
      surgery with mastectomy or lumpectomy and axillary lymph node dissection.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Response Rate</measure>
    <time_frame>7 years</time_frame>
    <description>Evaluate the pathological response rate of sequential doxorubicin and docetaxel chemotherapy in the neoadjuvant treatment of women with stage III breast cancer. Pathologic response is classified as either complete pathologic response or partial pathologic response based on the size of residual tumor after treatment (complete pathologic response if 0 cm, partial pathologic response if &gt;0 cm).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose-Dense Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <arm_group_label>Dose-Dense Chemotherapy</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Dose-Dense Chemotherapy</arm_group_label>
    <other_name>TaxotereÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Dose-Dense Chemotherapy</arm_group_label>
    <other_name>doxorubicin hydrochloride</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.</description>
    <arm_group_label>Dose-Dense Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or pathologically confirmed stage III breast cancer&#xD;
&#xD;
               -  Clinical evidence of primary invasive breast tumor greater than 5 cm in dimension&#xD;
                  (T3) and no evidence of metastatic disease clinically or by staging studies&#xD;
                  including computed tomography (CT) scan of the chest, abdomen, and pelvis, and a&#xD;
                  bone scan&#xD;
&#xD;
          -  Inflammatory breast carcinoma defined as diffuse brawny induration of the skin of the&#xD;
             breast with an erysipeloid edge due to embolization of the dermal lymphatics and&#xD;
             pathologic evidence of dermal lymphatic invasion&#xD;
&#xD;
          -  No bilateral breast cancer unless synchronous&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 4 times ULN provided SGOT/SGPT no greater than&#xD;
             ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  If prior cardiac event or ischemia on electrocardiogram, must be cleared by&#xD;
             cardiologist&#xD;
&#xD;
          -  LVEF at least 50% by resting MUGA&#xD;
&#xD;
          -  No severe cardiac dysfunction&#xD;
&#xD;
          -  No prior or concurrent angina pectoris, congestive heart failure, or major ventricular&#xD;
             arrhythmias&#xD;
&#xD;
          -  No uncontrolled essential hypertension&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal barrier contraception&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated basal cell&#xD;
             or squamous cell skin cancer, carcinoma in situ of the cervix, or intraductal or&#xD;
             lobular carcinoma in situ of the breast&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study consent or&#xD;
             treatment&#xD;
&#xD;
          -  No prior severe and intolerable reactions to filgrastim (G-CSF)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to the breast&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Minton, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>October 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2003</study_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

